Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2'-O-fucosyllactose + Humiome Post LB
- Development stage
- Unknown
- Lead developer
- DSM-Firmenich
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
2'-O-fucosyllactose + Humiome Post LB is a combination dietary supplement being evaluated for the treatment of Irritable Bowel Syndrome (IBS) and associated gastrointestinal symptoms. The formulation consists of 2'-O-fucosyllactose (2'-FL), a human milk oligosaccharide (HMO) that acts as a prebiotic, and Humiome Post LB, a heat-treated postbiotic containing inactivated strains of Limosilactobacillus fermentum (CNCM I-2998) and Lactobacillus delbrueckii (CNCM I-4831). Developed by DSM Nutritional Products and distributed by Stratum Nutrition, the combination aims to modulate the gut microbiota and improve gut barrier function to alleviate abdominal pain, bloating, and bowel irregularities. It is currently undergoing clinical testing in various dosage ratios to determine its efficacy in IBS patients.
- Other names
- 2'-FL + Humiome Post LBHMO-2FL + Humiome Post LB
Beyond the preview
Go deeper on 2'-O-fucosyllactose + Humiome Post LB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2'-O-fucosyllactose + Humiome Post LB.